NEW YORK (GenomeWeb News) – Shares of Pacific Biosciences climbed 12 percent in Friday afternoon trade after regulatory documents filed Thursday showed that Mike Hunkapiller, the firm's chairman, president, and CEO, had purchased 200,000 shares of the firm's stock on the open market.

According to a Form 4 filed with the US Securities and Exchange Commission, Hunkapiller bought the shares in multiple transactions at prices ranging from $3.51 to $3.72 and at an average price of $3.61 per share. Hunkapiller now owns 1.7 million shares of the firm's stock, according to the filing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.